ViewPoints Interview: Kaia Health’s Jonas Duss Shares Insights on COPD Pulmonary Rehabilitation App
Shots: Shots: The P-III ADVANCE study involves assessing of Otezla (apremilast, 30mg, bid for 16wks.) vs PBO in 595 patients in a ratio (1:1) with mild-to-moderate plaque psoriasis. Later, patients will receive Otezla during an open-label extension phase @32wks. The P-III ADVANCE study results: @16wks., improvement in its 1EPs of sPGA score; achieve 2EPs i.e, […]Read More